Hydroxyurea (Hydroxyurea) - Summary

HYDROXYUREA SUMMARY

Hydroxyurea, an antineoplastic agent, available for oral use as capsules. Each capsule, for oral administration contains 500 mg hydroxyurea.

Hydroxyurea is indicated for the following:

Significant tumor response to hydroxyurea capsules, USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary.

Hydroxyurea used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

See all Hydroxyurea indications & dosage >>

HYDROXYUREA NEWS HIGHLIGHTS

Published Studies Related to Hydroxyurea

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. [2007.11]

Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. [2007.07.01]

Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. [2006.12]

Hydroxyurea and sickle cell anemia: effect on quality of life. [2006.08.31]

The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). [2006.06]

more >>

Clinical Trials Related to Hydroxyurea

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma [Completed]

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Active, not recruiting]

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Active, not recruiting]

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients [Completed]

Hydroxyurea in Young Children With Sickle Cell Anemia [Completed]

more >>